Table 2.
In vitro activity of azole agents against 90 clinical isolates of T. asahiia
| Agent | MIC or MFC | MIC (μg/ml) at 24 h |
MIC (μg/ml) at 48 h |
% Agreementb (±1 dilution) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Range | MIC50 or MFC50 | MIC90 or MFC90 | GM | Range | MIC50 or MFC50 | MIC90 or MFC90 | GM | |||
| Fluconazole | MIC-2 | ≤0.12–8 | 1 | 4 | 1.54 | 0.5–16 | 4 | 8 | 3.24 | 64.4 |
| MIC-0 | 2–32 | 8 | 32 | 10.66 | 4–32 | 8 | 32 | 11.31 | 98.9 | |
| MFC | 2–64 | 16 | 64 | 20.78 | 4–64 | 32 | 64 | 23.69 | ||
| Itraconazole | MIC-2 | 0.03–1 | 0.25 | 0.5 | 0.23 | 0.12–1 | 0.25 | 1 | 0.37 | 78.9 |
| MIC-0 | 0.5–2 | 1 | 2 | 1.06 | 0.5–4 | 2 | 2 | 1.44 | 98.9 | |
| MFC | 1–>8 | 2 | 8 | 2.43 | 1–>8 | 2 | 8 | 3.1 | ||
| Voriconazole | MIC-2 | ≤0.015–0.12 | 0.03 | 0.06 | 0.04 | ≤0.015–0.25 | 0.06 | 0.12 | 0.06 | 75.6 |
| MIC-0 | 0.06–0.5 | 0.25 | 0.5 | 0.21 | 0.12–0.5 | 0.25 | 0.5 | 0.25 | 98.9 | |
| MFC | 0.25–4 | 0.5 | 2 | 0.71 | 0.25–8 | 1 | 2 | 0.83 | ||
| Posaconazole | MIC-2 | ≤0.015–1 | 0.12 | 0.5 | 0.16 | 0.06–1 | 0.25 | 0.5 | 0.25 | 76.7 |
| MIC-0 | 0.5–2 | 1 | 1 | 1.06 | 1–2 | 1 | 2 | 1.12 | 100 | |
| MFC | 0.5–8 | 2 | 2 | 1.68 | 0.5–8 | 2 | 4 | 1.92 | ||
| Isavuconazole | MIC-2 | ≤0.015–0.5 | 0.03 | 0.25 | 0.07 | ≤0.015–0.5 | 0.12 | 0.25 | 0.1 | 67.8 |
| MIC-0 | 0.12–2 | 0.5 | 1 | 0.53 | 0.25–2 | 1 | 1 | 0.75 | 97.8 | |
| MFC | 0.5–8 | 2 | 4 | 1.79 | 0.5–8 | 2 | 4 | 2.14 | ||
a
MIC-2 and MIC-0, MICs that inhibit 50 and 100% of growth, respectively; MIC50 and MIC90, concentrations that inhibit 50 and 90% of isolates, respectively; MFC, minimum fungicidal concentration; GM, geometric mean.
b
That is, agreement between results obtained at 24 and 48 h.